Liquidata Share/ETF/Trust Analysis
Portfolio Holdings Detail for ISIN IE00BYXG2H39
| Stock Name / Fund | iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) |
| Issuer | Blackrock |
| Entity holding fund | iShares IV Public Limited Company |
| Entity Type | Umbrella investment company with variable capital and having segregated liability between its funds |
| Entity LEI | 549300ZP07LMR36K1T02 |
| ETF Ticker | BTEC(USD) LSE |
| ETF Ticker | BTEK(GBP) LSE |
| ETF Ticker | 2B70(EUR) F |
| ETF Ticker | 2B70.DE(EUR) CXE |
| ETF Ticker | BTEC.LS(USD) CXE |
| ETF Ticker | BTEK.LS(GBP) CXE |
| ETF Ticker | BTEC.L(GBP) LSE |
| ETF Ticker | BTEK.L(GBP) LSE |
Holdings detail for FATE
| Stock Name | Fate Therapeutics Inc |
| Ticker | FATE(USD) NASDAQ |
| TYPE | Common Stock |
| Country | USA |
| ISIN | US31189P1021 |
| LEI | 549300L14Q4UHOODLA90 |
Show aggregate FATE holdings
News associated with FATE
- Fate Therapeutics (NASDAQ:FATE) & Cyclerion Therapeutics (NASDAQ:CYCN) Head-To-Head Analysis
- Fate Therapeutics (NASDAQ:FATE – Get Free Report) and Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their institutional ownership, dividends, analyst recommendations, profitability, risk, valuation and earnings. Risk & Volatility Fate Therapeutics has a […] - 2025-08-29 02:14:49
- Brokerages Set Fate Therapeutics, Inc. (NASDAQ:FATE) Price Target at $3.83
- Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been assigned an average rating of “Hold” from the eight ratings firms that are covering the company, Marketbeat reports. Seven equities research analysts have rated the stock with a hold recommendation and one has issued a buy recommendation on the company. The average 1 […] - 2025-06-24 02:54:47
- Squarepoint Ops LLC Purchases 20,805 Shares of Fate Therapeutics, Inc. (NASDAQ:FATE)
- Squarepoint Ops LLC grew its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 154.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 34,295 shares of the biopharmaceutical company’s stock after acquiring an additional 20,805 […] - 2025-06-11 05:08:50
- Bank of America Corp DE Reduces Position in Fate Therapeutics, Inc. (NASDAQ:FATE)
- Bank of America Corp DE lessened its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 64.4% in the 4th quarter, Holdings Channel reports. The institutional investor owned 304,129 shares of the biopharmaceutical company’s stock after selling 550,066 shares during the quarter. Bank of America Corp DE’s holdings in Fate Therapeutics were […] - 2025-06-11 04:14:58
- Graham Capital Management L.P. Buys New Shares in Fate Therapeutics, Inc. (NASDAQ:FATE)
- Graham Capital Management L.P. bought a new stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 22,342 shares of the biopharmaceutical company’s stock, valued at approximately $37,000. Other large investors […] - 2025-05-20 05:40:49
- D. E. Shaw & Co. Inc. Decreases Position in Fate Therapeutics, Inc. (NASDAQ:FATE)
- D. E. Shaw & Co. Inc. lessened its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 54.5% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 1,536,633 shares of the biopharmaceutical company’s stock after selling 1,841,017 shares […] - 2025-05-20 04:56:58
- Hsbc Holdings PLC Has $179,000 Stock Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)
- Hsbc Holdings PLC grew its stake in Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 22.0% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 109,422 shares of the biopharmaceutical company’s stock after purchasing an additional 19,706 shares during the quarter. Hsbc […] - 2025-05-12 04:56:49
- Fate Therapeutics, Inc. (NASDAQ:FATE) Receives $5.43 Consensus PT from Analysts
- Shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Get Free Report) have been given a consensus rating of “Hold” by the nine research firms that are presently covering the firm, Marketbeat reports. Seven equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. The average […] - 2025-05-05 03:13:09
- CANADA LIFE ASSURANCE Co Has $35,000 Stock Position in Fate Therapeutics, Inc. (NASDAQ:FATE)
- CANADA LIFE ASSURANCE Co trimmed its position in Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 53.4% in the fourth quarter, Holdings Channel.com reports. The firm owned 21,267 shares of the biopharmaceutical company’s stock after selling 24,365 shares during the period. CANADA LIFE ASSURANCE Co’s holdings in Fate Therapeutics were worth $35,000 at the end […] - 2025-05-01 05:50:46
- Marshall Wace LLP Makes New Investment in Fate Therapeutics, Inc. (NASDAQ:FATE)
- Marshall Wace LLP bought a new position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 512,641 shares of the biopharmaceutical company’s stock, valued at approximately $846,000. Marshall Wace LLP owned approximately 0.45% of Fate […] - 2025-05-01 04:53:01
- Cerity Partners LLC Grows Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)
- Cerity Partners LLC boosted its holdings in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 4,953.6% during the 4th quarter, according to its most recent 13F filing with the SEC. The fund owned 823,134 shares of the biopharmaceutical company’s stock after purchasing an additional 806,846 shares during the period. Cerity Partners LLC owned […] - 2025-04-18 05:06:56
- Fate Therapeutics, Inc. (NASDAQ:FATE) Shares Sold by Prudential Financial Inc.
- Prudential Financial Inc. trimmed its position in shares of Fate Therapeutics, Inc. (NASDAQ:FATE – Free Report) by 9.9% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 321,401 shares of the biopharmaceutical company’s stock after selling 35,200 shares during the […] - 2025-04-09 04:51:00
- Fate Therapeutics (NASDAQ:FATE) Lowered to “Sell” Rating by StockNews.com
- StockNews.com cut shares of Fate Therapeutics (NASDAQ:FATE – Free Report) from a hold rating to a sell rating in a research note issued to investors on Tuesday. FATE has been the topic of a number of other reports. Stifel Nicolaus cut their target price on Fate Therapeutics from $5.00 to $3.00 and set a “hold” […] - 2025-03-12 04:42:57
- Fate Therapeutics (NASDAQ:FATE) Upgraded by StockNews.com to Hold Rating
- Fate Therapeutics (NASDAQ:FATE – Get Free Report) was upgraded by investment analysts at StockNews.com from a “sell” rating to a “hold” rating in a research note issued to investors on Monday. A number of other research firms have also issued reports on FATE. Wedbush reaffirmed a “neutral” rating and set a $5.00 target price on […] - 2025-03-05 04:52:57
iShares Nasdaq US Biotechnology UCITS ETF USD (Acc) FATE holdings
| Date | Number of FATE Shares Held | Base Market Value of FATE Shares | Local Market Value of FATE Shares | Change in FATE Shares Held | Change in FATE Base Value | Current Price per FATE Share Held | Previous Price per FATE Share Held |
|---|
| 2025-11-11 (Tuesday) | 69,972 | USD 78,369 | USD 78,369 | 0 | USD 2,100 | USD 1.12001 | USD 1.08999 |
| 2025-11-10 (Monday) | 69,972 | USD 76,269 | USD 76,269 | 187 | USD 1,599 | USD 1.08999 | USD 1.07 |
| 2025-11-07 (Friday) | 69,785 | USD 74,670 | USD 74,670 | 0 | USD 2,094 | USD 1.07 | USD 1.03999 |
| 2025-11-06 (Thursday) | 69,785 | USD 72,576 | USD 72,576 | 187 | USD -3,286 | USD 1.03999 | USD 1.09 |
| 2025-11-05 (Wednesday) | 69,598 | USD 75,862 | USD 75,862 | 0 | USD -6,960 | USD 1.09 | USD 1.19001 |
| 2025-11-04 (Tuesday) | 69,598 | USD 82,822 | USD 82,822 | 187 | USD -4,636 | USD 1.19001 | USD 1.26 |
| 2025-11-03 (Monday) | 69,411 | USD 87,458 | USD 87,458 | 0 | USD -6,247 | USD 1.26 | USD 1.35 |
| 2025-10-31 (Friday) | 69,411 | USD 93,705 | USD 93,705 | 0 | USD 4,165 | USD 1.35 | USD 1.29 |
| 2025-10-30 (Thursday) | 69,411 | USD 89,540 | USD 89,540 | 935 | USD -2,218 | USD 1.29 | USD 1.34 |
| 2025-10-29 (Wednesday) | 68,476 | USD 91,758 | USD 91,758 | 374 | USD -9,714 | USD 1.34 | USD 1.49 |
| 2025-10-28 (Tuesday) | 68,102 | USD 101,472 | USD 101,472 | 0 | USD -4,086 | USD 1.49 | USD 1.55 |
| 2025-10-27 (Monday) | 68,102 | USD 105,558 | USD 105,558 | 0 | USD -6,810 | USD 1.55 | USD 1.65 |
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdingsShare Trades of FATE by Blackrock for IE00BYXG2H39
Show aggregate share trades of FATE| Date | Action | Quantity | Market High | Market Low | Likely Trade Price | Likely Trade Value (Profit/Loss) | Average Price previous trades |
|---|
| 2025-11-10 | BUY | 187 | 1.120 | 1.050 | 1.057 | USD 198 | 1.18 |
| 2025-11-06 | BUY | 187 | 1.140 | 1.030 | 1.041 | USD 195 | 1.18 |
| 2025-11-04 | BUY | 187 | 1.300 | 1.185 | 1.196 | USD 224 | 1.18 |
| 2025-10-30 | BUY | 935 | 1.380 | 1.280 | 1.290 | USD 1,206 | 1.18 |
| 2025-10-29 | BUY | 374 | 1.340 | 1.487 | 1.472 | USD 551 | 1.18 |
| 2025-10-22 | SELL | -748 | 1.490 | 1.580 | 1.571 | USD -1,175 | 1.17 Loss of -302 on sale |
| 2025-10-20 | BUY | 374 | 1.540 | 1.560 | 1.558 | USD 583 | 1.16 |
| 2025-10-17 | BUY | 931 | 1.470 | 1.530 | 1.524 | USD 1,419 | 1.16 |
| 2025-10-15 | BUY | 1,472 | 1.530 | 1.530 | 1.530 | USD 2,252 | 1.16 |
| 2025-10-03 | BUY | 1,309 | 1.210 | 1.230 | 1.228 | USD 1,607 | 1.15 |
| 2025-10-02 | BUY | 187 | 1.210 | 1.250 | 1.246 | USD 233 | 1.15 |
| 2025-10-01 | BUY | 374 | 1.250 | 1.370 | 1.358 | USD 508 | 1.15 |
| 2025-09-26 | BUY | 374 | 1.000 | 1.010 | 1.009 | USD 377 | 1.15 |
| 2025-09-25 | BUY | 372 | 0.970 | 1.000 | 0.997 | USD 371 | 1.16 |
| 2025-09-18 | BUY | 186 | 1.000 | 1.020 | 1.018 | USD 189 | 1.16 |
| 2025-09-17 | BUY | 558 | 0.950 | 1.010 | 1.004 | USD 560 | 1.16 |
| 2025-08-20 | SELL | -748 | 1.130 | 1.150 | 1.148 | USD -859 | 1.16 Profit of 11 on sale |
| 2025-07-30 | BUY | 744 | 1.140 | 1.230 | 1.221 | USD 908 | 1.17 |
| 2025-07-17 | SELL | -374 | 1.150 | 1.180 | 1.177 | USD -440 | 1.16 Loss of -5 on sale |
| 2025-07-11 | SELL | -1,496 | 1.150 | 1.170 | 1.168 | USD -1,747 | 1.16 Loss of -6 on sale |
| 2025-07-07 | BUY | 561 | 1.060 | 1.130 | 1.123 | USD 630 | 1.17 |
| 2025-07-02 | BUY | 10,175 | 1.120 | 1.220 | 1.210 | USD 12,312 | 1.17 |
| 2025-06-11 | BUY | 370 | 1.550 | 1.740 | 1.721 | USD 637 | 1.16 |
| 2025-06-10 | BUY | 370 | 1.670 | 1.820 | 1.805 | USD 668 | 1.15 |
| 2025-06-04 | SELL | -185 | 1.420 | 1.450 | 1.447 | USD -268 | 1.14 Loss of -57 on sale |
| 2025-04-23 | BUY | 185 | 1.330 | 1.490 | 1.474 | USD 273 | 1.12 |
| 2025-04-10 | SELL | -1,488 | 0.940 | 0.960 | 0.958 | USD -1,426 | 1.12 Profit of 243 on sale |
| 2025-04-08 | SELL | -372 | 0.910 | 0.990 | 0.982 | USD -365 | 1.13 Profit of 55 on sale |
| 2025-04-04 | SELL | -930 | 0.750 | 0.760 | 0.759 | USD -706 | 1.14 Profit of 356 on sale |
| 2025-04-01 | BUY | 744 | 0.760 | 0.800 | 0.796 | USD 592 | 1.16 |
| 2025-03-31 | SELL | -558 | 0.790 | 0.830 | 0.826 | USD -461 | 1.17 Profit of 189 on sale |
| 2025-03-14 | SELL | -2,976 | 0.940 | 0.970 | 0.967 | USD -2,878 | 1.24 Profit of 822 on sale |
| 2025-03-07 | SELL | -372 | 1.010 | 1.060 | 1.055 | USD -392 | 1.29 Profit of 86 on sale |
| 2025-03-04 | SELL | -186 | 0.950 | 1.010 | 1.004 | USD -187 | 1.32 Profit of 59 on sale |
| 2025-02-25 | BUY | 372 | 1.230 | 1.370 | 1.356 | USD 504 | 1.36 |
| 2025-02-19 | SELL | -186 | 1.710 | 1.810 | 1.800 | USD -335 | 1.33 Loss of -87 on sale |
| 2025-02-13 | BUY | 558 | 1.270 | 1.280 | 1.279 | USD 714 | 1.31 |
| 2025-02-12 | BUY | 186 | 1.250 | 1.260 | 1.259 | USD 234 | 1.32 |
| 2025-02-11 | BUY | 744 | 1.210 | 1.250 | 1.246 | USD 927 | 1.33 |
Market high and low price is on the date. * (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection
The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close
Shorting History of FATE
| Date | Shorted Volume | Short Exempt Volume | Total Shares Traded | % Shorted |
|---|
| 2025-09-19 | 373,980 | 0 | 796,624 | 46.9% |
| 2025-09-18 | 183,259 | 0 | 872,793 | 21.0% |
| 2025-09-17 | 380,141 | 1,298 | 911,798 | 41.7% |
| 2025-09-16 | 176,271 | 2,009 | 486,904 | 36.2% |
| 2025-09-15 | 413,558 | 0 | 746,435 | 55.4% |
| 2025-09-12 | 435,185 | 3,037 | 892,419 | 48.8% |
| 2025-09-11 | 325,320 | 0 | 794,408 | 41.0% |
| 2025-09-10 | 491,448 | 40,604 | 1,057,893 | 46.5% |
| 2025-09-09 | 365,204 | 2 | 861,030 | 42.4% |
| 2025-09-08 | 404,614 | 28,783 | 706,452 | 57.3% |
| 2025-09-05 | 511,946 | 827 | 1,114,791 | 45.9% |
| 2025-09-04 | 531,652 | 0 | 1,051,491 | 50.6% |
| 2025-09-03 | 275,639 | 0 | 672,394 | 41.0% |
| 2025-09-02 | 186,141 | 0 | 460,221 | 40.4% |
| 2025-08-29 | 173,090 | 280 | 514,782 | 33.6% |
| 2025-08-28 | 182,875 | 2,388 | 422,900 | 43.2% |
| 2025-08-27 | 167,477 | 500 | 398,709 | 42.0% |
| 2025-08-26 | 199,066 | 0 | 566,034 | 35.2% |
| 2025-08-25 | 446,389 | 0 | 1,576,496 | 28.3% |
| 2025-08-22 | 304,741 | 0 | 838,359 | 36.3% |
| 2025-08-21 | 164,763 | 0 | 446,895 | 36.9% |
| 2025-08-20 | 122,150 | 7,328 | 433,462 | 28.2% |
| 2025-08-19 | 761,853 | 54,797 | 1,125,323 | 67.7% |
| 2025-08-18 | 343,383 | 50 | 830,462 | 41.3% |
| 2025-08-15 | 430,718 | 5,432 | 961,487 | 44.8% |
| 2025-08-14 | 343,200 | 0 | 1,047,929 | 32.8% |
| 2025-08-13 | 1,529,521 | 27,556 | 3,479,757 | 44.0% |
| 2025-08-12 | 208,913 | 0 | 528,290 | 39.5% |
| 2025-08-11 | 163,281 | 0 | 458,859 | 35.6% |
| 2025-08-08 | 442,989 | 27,569 | 907,526 | 48.8% |
| 2025-08-07 | 466,279 | 28,301 | 904,787 | 51.5% |
| 2025-08-06 | 228,226 | 1,411 | 452,053 | 50.5% |
| 2025-08-05 | 237,345 | 0 | 577,199 | 41.1% |
| 2025-08-04 | 137,459 | 5 | 487,802 | 28.2% |
| 2025-08-01 | 119,052 | 0 | 419,814 | 28.4% |
| 2025-07-31 | 213,321 | 1,190 | 501,162 | 42.6% |
| 2025-07-30 | 143,872 | 10,418 | 696,731 | 20.6% |
| 2025-07-29 | 244,253 | 9,076 | 1,097,120 | 22.3% |
| 2025-07-28 | 244,585 | 10,760 | 1,146,969 | 21.3% |
| 2025-07-25 | 189,954 | 0 | 546,222 | 34.8% |
| 2025-07-24 | 362,217 | 0 | 1,063,601 | 34.1% |
| 2025-07-23 | 213,102 | 588 | 1,464,756 | 14.5% |
| 2025-07-22 | 405,374 | 19,270 | 1,962,875 | 20.7% |
| 2025-07-21 | 100,695 | 148 | 560,902 | 18.0% |
| 2025-07-18 | 93,047 | 0 | 611,176 | 15.2% |
The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.
Back to Listing
Disclaimer
All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.